Enteric fever, commonly known as typhoid, is a life-threatening illness caused by the Salmonella Typhi bacteria. The disease remains a significant health concern, particularly in developing countries. This article aims to provide an updated approach to managing enteric fever effectively.
Accurate diagnosis of enteric fever is critical for successful management. Blood culture remains the gold standard, but its sensitivity is limited. Recent advances include PCR and antigen detection tests, offering improved sensitivity and specificity.
Antibiotic therapy is the cornerstone of treatment. Fluoroquinolones were once the first-line treatment, but increasing resistance has necessitated a shift towards third-generation cephalosporins and azithromycin. The choice of antibiotic should be guided by local susceptibility patterns.
Vaccination plays a pivotal role in the prevention of enteric fever. Two vaccines are currently available: Vi polysaccharide vaccine and Ty21a vaccine. Both offer substantial protection and are recommended for individuals in endemic areas and travelers to these regions.
Public health measures are integral to controlling enteric fever. These include ensuring access to clean water, improving sanitation, and promoting hand hygiene. Rapid identification and treatment of cases can also help limit transmission.
Novel diagnostic tools and vaccines are under development, promising improved management of enteric fever. However, addressing the social determinants of health is crucial to achieving lasting progress.
In conclusion, the management of enteric fever requires a multifaceted approach, encompassing accurate diagnosis, appropriate antibiotic therapy, vaccination, and public health measures. Future efforts should focus on the development of novel interventions and addressing the underlying social determinants of the disease.
1.
Trial Supports Ivonescimab and Chemo for NSCLC Survival
2.
Cancer "Tidal Wave" Prediction: Not Cigarette-Based, Either! Wary Stories Regarding Cannabis and Cancer.
3.
Lymph node transfer reduces arm swelling after breast cancer surgery, study shows
4.
Silibinin is a novel and ancient molecule that highlights the significance of integrated therapies for cancer.
5.
Research Indicates that First-Line Immunotherapy Is Enough for Elderly NSCLC Patients?
1.
Unlocking the Power of Hematocrit: Exploring the Benefits of Blood Cell Counts
2.
Unpacking Chordoma: Understanding the Rare Cancer and its Treatment Options
3.
Colorectal Cancer Incidence Trends: A Growing Concern in 2024 and 2025
4.
Uncovering the Mysteries of the RDW Blood Test
5.
The Basics of Langerhans Cell Histiocytosis: Understanding a Rare Disease
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Navigating the Complexities of Ph Negative ALL - Part II
2.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management
3.
Targeting Oncologic Drivers: A New Approach to Lung Cancer Treatment
4.
The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift
5.
Navigating the Complexities of Ph Negative ALL - Part XIV
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation